Last-line multiple myeloma patients, who have exhausted other treatment options have been responding to oral drug inobrodib in combination with pomalidomide and dexamethasone (pom and dex).
Today, world-leading generative artificial intelligence (AI) company for life sciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
Virtual research organization, ObvioHealth, has just announced the launch of its application programming interface (API) which it says is tailored specifically for digital therapeutics (DTx) clinical trials.
The first six companies enter the Deep Tech Lab - Quantum start-up accelerator at BioInnovation Institute (BII) to unlock the potential in quantum science
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Sofia Baig is the president of clinical solutions at Precision for Medicine. As a strategic industry leader, she is adept driving organizational change and delivering top- and bottom-line growth.
Professor Deborah Ashby, interim Dean of the Faculty of Medicine, Imperial College, delivered this year’s Sally Hollis Memorial Lecture. OSP enjoyed a discussion with both her and Professor Jennifer Visser-Rogers, vice-president for statistical research...
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.
An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).
CluePoints, a company providing risk-based study execution (RBx) and risk-based quality management (RBQM) software for clinical trials has won the best Contract Research Organization (CRO) in the specialist providers category at Citeline’s 2023 SCRIP...
OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc. to discuss a number of issues those working in precision medicine still face.
OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at...
A small molecule, oral targeted therapy for adults with metastatic colorectal cancer (CRC) has been approved by the US Food and Drug Administration (FDA).
Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.
myTrialsConnect, a research community powered by artificial intelligence (AI) has been launched following a partnership between Elligo Health Research and Avallano.
Executive director of Medical Research Network's (MRN's) digital health, Edward Triebell, joined OSP for a Q&A where he shared some interesting shifts and statistics about digital trends in clinical research.
From Disney to the drug world, Liss Easy has had a fascinating journey to where she is now in her role as vice president and general manager of clinical operations at IQVIA.
Unfortunately, more than 700 rare diseases affect more than 30 million people in the US alone and with many of them being life threatening, it is still a concern that most still do not have treatments.
OSP had a quickfire interview with Rebecca Starkie, senior global patient engagement director, at Advanced Clinical where she explains the challenges faced by rare disease patients - and suggests ways to improve.
Element Biosciences, Inc., will share news of its sequencing methodology and host a workshop on higher accuracy sequencing for improved variant detection in Washington DC from today.
A transaction between Citius Pharmaceuticals and TenX Keane which will result in the formation of Citius Oncology, Inc. is due to close in the first half of next year (2024).
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.
Advanced tech company, PhaseV, has raised $15 million in funding that it says it will use to ‘push the boundaries of machine learning for clinical trial optimization’.
Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimer’s Disease can bring quality of life to patients.
Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Saama, a provider of artificial intelligence (AI) based solutions, announced today (October 17) that it has formed a multi-year agreement with biopharma giant, AstraZeneca.
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.
Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the company’s drug, setanaxib in Alport Syndrome (AS).
